secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2025-05-16T23:59:59+00:00
Accession:  0001641172-25-011286
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata Therapeutics faces Nasdaq delisting for minimum bid price; plans hearing
--------------------------------------------------------------------------------

- Regained compliance with Nasdaq stockholders' equity requirement on May 14, 2025.
- Received notice of non-compliance with $1.00 minimum bid price; securities subject to delisting.
- Reverse stock split within past year triggers accelerated delisting; suspension possible May 23, 2025.
- Company plans to request hearing by May 21, 2025 to stay suspension pending panel decision.
- No assurance compliance plan will be accepted; delisting risk remains if plan fails.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000164117225011286/0001641172-25-011286-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000164117225011286/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-011286

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer